27th Dec 2019 09:19
27 December 2019
Cathay International Holdings Limited
("Cathay" or the "Company")
Increase in shareholder loan
Reference is made to the Company's announcement on 22 November 2019 relating to the USD23 million loan facility (the "Loan Facility") from Cathay International EW No. 43 Limited ("CIEW43"), a company controlled by Mr. Wu, the Chairman of the Company.
The Company announces that it has further agreed with CIEW43 today to increase the Loan Facility by USD11 million to USD34 million for the Group's working capital. As disclose in the previous announcement, the Loan Facility is on normal commercial terms, has an initial term of 1 year, interest is payable at the rate of LIBOR +3.5% per annum and is unsecured. In addition, the loan is repayable in certain events of default or in the event that the Company raises capital through the sale of assets or otherwise.
- ENDS -
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Patrick Sung (Director and Controller)
|
Tel: +852 2828 9289 |
Consilium Strategic Communications Mary-Jane Elliott / Matthew Neal / Lindsey Neville
|
Tel: +44 (0) 203 709 5702
|
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 1,500 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.
Related Shares:
CTI.L